Bimatoprost ophthalmic solution 0,03%: a simple and effective treatment of the eyelashes
Macedo O, Carvalho CC, Matayoshi L, Tsuji L
Bimatoprost ophthalmic solution 0,03% is a medication used to treat intraocular pressure in patients with open angle glaucoma or ocular hypertension, approved in 2001. The new indication for this solution is the treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. It is applied at night to the skin of the upper eyelid margin at the base of the eyelashes using a disposable applicator (one for each eye), which is to be used only once. Exactly how bimatoprost, a prostaglandin analog, promotes eyelash growth has not been determined, but growth is believed to occur by increasing the percentage of hairs in, and the duration of, the anagen or growth phase, according to the labeling.
The purpose of this study was to evaluate the efficacy and safety of Bimatoprost ophthalmic solution 0,03%.
Ten patients, 25 to 50 years, phototype I-IV, were submitted to treatment during 90 days.The Bimatoprost ophthalmic solution 0,03%.was applied exclusively in the skin of the eyelid margins higher, on the bases of eyelashes,once a day and one drop for each eyelid. Documentation with Visia Digital Photographic system was made before and 3 months after. The eyelashes were compared according their length, thickness and darkness during the visits.
80% of the patients reported increase of the lengh, 76% reported darkness and 72% reported increase of the thickness. None of them apresented side effects. The mos common adverse events are eye pruritus, conjunctival hyperemia, and skin hyperpigmentation. Warnings include the possibility of pigmentation of the iris (which is likely to be permanent) and the eyelids.
Bimatoprost ophthalmic solution 0,03%.is a new, safe and effective option for the patients with hypotrichosis of the eyelashes when used correctly.
1.Gowrishankar TR, Stewart DA, Martin GT, Weaver JC. Transport lattice models of heat transport in
skin with spatially heterogeneous, temperature-dependent perfusion. Biomed Eng Online
2.Berube D, Renton B, Hantash BM. A predictive model os minimally invasive bipolar fractional radiofrequency skin treatment. Laser in Surgery and medicine 2009; 41(7): 473-478.
3.Zelickson BD, Kist D, Bernstein E, Brown DB, Ksenzenko S, Burns J, Kilmer S, Mehregan D, Pope K.
Histological and ultrastructure evaluation of the effects of a radiofrequency-based nonablative dermal remodeling device- A pilot studey. Arch Dermatol 2004;140(2):204-209.
4.Aksan A, McGrath JJ, Nielubowicz DS. Thermal damage prediction for collagenous tissues part I: A clinically relevant numerical simulation incorporating heating rate dependant denaturation. J Biomech Eng 205;127:85-97.
5.Jiang SC, Ma N, Li HJ, Zhang XX. Effects of thermal properties and geometrical dimensions on skin burn injuries. Burns 2002;28(8):713-717.